US FDA calls Taxotere promotion misleading
This article was originally published in Scrip
Executive Summary
A promotion for Sanofi-Aventis's taxane chemotherapeutic Taxotere (docetaxel) was misleading because it presented unsubstantiated superiority claims against paclitaxel (Bristol-Myers Squibb's Taxol and generics), the US FDA's division of drug marketing, advertising and communications (DDMAC) said.